-
Ninth listing of 2022 on Euronext Growth Milan
-
Laboratorio Farmaceutico Erfo S.p.A. brings the total number of companies listed on Euronext Growth Milan to 179
-
Total placement volume of the offering equal to €3.45 million
Milan – 29 June 2022 – Borsa Italiana, part of the Euronext Group, today congratulates Laboratorio Farmaceutico Erfo S.p.A on its listing on Euronext Growth Milan.
Laboratorio Farmaceutico Erfo S.p.A is an innovative SME operating in the nutraceutical sector. The company specialises in the formulation and production of food supplements which, thanks to continuous R&D carried out internally and in collaboration with the University of Rome’s “Campus Bio-Medico” and the University of Messina, are marketed following market trends and consumer needs.
Laboratorio Farmaceutico Erfo S.p.A represents the ninth listing since the beginning of the year on Borsa Italiana’s market dedicated to small and medium sized companies, and it brings the total number of firms currently listed on Euronext Growth Milan to 179.
In the placement phase, Laboratorio Farmaceutico Erfo S.p.A raised €3.0 million excluding the potential exercise of an over-allotment option. In the case of the full exercise of the over-allotment option, the total amount raised will be €3.45 million.
The free float at the time of admission was 22.22% and the market capitalisation at IPO was €13.5 million.
Alex Cutè, CEO and Founder of Laboratorio Farmaceutico Erfo S.p.A., said: "It is a source of pride and satisfaction for me to celebrate the achievement of this ambitious goal. The listing of ERFO is an important step along the journey towards internationalisation. The IPO’s proceeds will accelerate the achievement of our strategic objectives, aimed at consolidating our business model, characterised by a high degree of innovation and scalability. We have a solid financial base that in 2021 allowed us to grow at a CAGR of 26% during 2013-21, together with high profitability and zero debt."
Caption: Alex Cutè, CEO and Founder, rang the bell during the market open ceremony this morning to celebrate the Initial Public Offering of the company.
About Laboratorio Farmaceutico Erfo S.p.A. Laboratorio Farmaceutico Erfo S.p.A., founded in 2013, is an innovative SME operating in the nutraceutical sector. The company specialises in the formulation and production of food supplements which, thanks to continuous R&D carried out internally and in collaboration with the University of Rome “Campus Bio-Medico” and the University of Messina, are commercialised following the market trends and consumer needs. The Company has over 60 products in its portfolio manufactured through the use of latest generation industrial machinery.
The business model is developed through two strategic lines:
1. Diètnatural: business format franchise dedicated to the sale of nutraceutical products and ongoing assistance in the nutritional journey of each customer, through versatile and high-margin commercial formulas. These products, marketed under the “DiètNatural” brand, are distributed in proprietary single-brand centres, both owned and managed by franchisees.
2. Medical Division: new line of nutraceutical products launched in 2021, which are mainly distributed through pharmaceutical wholesalers to pharmacies and para-pharmacies. This business unit is dedicated to specific therapeutic areas: gastroenterology and urology.